Shigeyuki Matsui is a professor in the Department of Biostatistics at Nagoya University Graduate School of Medicine in Japan. He is also a visiting professor at the Institute of Statistical Mathematics. Dr. Matsui has served as council and nominating committee member of the International Biometric Society. He is currently council of the Biometric Society of Japan (BSJ) and editor-in-chief of the Japanese Journal of Biometrics. He is the recipient of the 2014 Award from the BSJ. Dr. Matsui is also a frequent reviewer commissioned by government and advisor to pharmaceutical companies in Japan. He holds degrees in engineering from the Tokyo University of Science in Japan.Marc E. Buyse is the founder of the International Drug Development Institute in Louvain-la-Neuve, Belgium and of CluePoints Inc. in Cambridge, Massachusetts. He is also an associate professor of biostatistics at Hasselt University in Belgium. He was president of the International Society for Clinical Biostatistics, president of the Quetelet Society, and fellow of the Society for Clinical Trials. He worked at the European Organization for Research and Treatment of Cancer in Brussels and at the Dana Farber Cancer Institute in Boston. He holds degrees in engineering and statistics from Brussels University, management from the Cranfield School of Management in the UK, and a doctorate in biostatistics from Harvard University.Richard M. Simon is chief of the Biometric Research Branch at the National Cancer Institute in Bethesda, Maryland. He leads a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. Dr. Simon is the architect of BRB-ArrayTools software used for the analysis of microarray and digital expression, copy number, and methylation data. He is the recipient of the 2013 Karl E. Peace Award for Outstanding Statistical Contributions for the Betterment of Society and is the author or coauthor of more than 450 publications.

• INTRODUCTORY OVERVIEW. Clinical Trials for Predictive Medicine: New Paradigms and Challenges. An Industry Statistician’s Perspective on Personalized Health Care Drug Development. Analytical Validation of In Vitro Diagnostic Tests. EARLY CLINICAL TRIALS USING BIOMARKERS. Phase I Dose-Finding Designs and Their Applicability to Targeted Therapies. An Overview of Phase II Clinical Trial Designs with Biomarkers. Bayesian Adaptive Methods for Clinical Trials of Targeted Agents. Outcome-Adaptive Randomization in Early Clinical Trials. Challenges of Using Predictive Biomarkers in Clinical Trials. PHASE III RANDOMIZED CLINICAL TRIALS USING BIOMARKERS. Comparison of Randomized Clinical Trial Designs for Targeted Agents. Phase III All-Comers Clinical Trials with a Predictive Biomarker. Evaluation of Clinical Utility and Validation of Gene Signatures in Clinical Trials. ANALYSIS OF HIGH-DIMENSIONAL DATA AND GENOMIC SIGNATURE DEVELOPMENTS. Statistical Issues in Clinical Development and Validation of Genomic Signatures. Univariate Analysis for Gene Screening: Beyond Multiple Testing. Statistical and Machine-Learning Methods for Class Prediction in High Dimension. Survival Risk Prediction Using High-Dimensional Molecular Data. RANDOMIZED TRIALS WITH BIOMARKER DEVELOPMENT AND VALIDATION. Adaptive Clinical Trial Designs with Biomarker Development and Validation. Development and Validation of Continuous Genomic Signatures in Randomized Clinical Trials. EVALUATION OF SURROGATE BIOMARKERS. Biomarker-Based Surrogate Endpoints.

"To say this is an extremely timely book would be a gross understatement. The editors have assembled an impressive series of articles that address many of the major methodological issues confronting researchers who are attempting to not only identify valuable medical treatments but to determine which subsets of patients will benefit from these treatments. These issues are particularly important in cancer research, where treatments are often burdensome, toxic, and expensive; one does not want to treat large numbers of patients when only a few will benefit …[this] would be a very valuable resource for anyone in, or moving into, the area of clinical trials for developing targeted therapies. Because the chapters steer away from highly technical discussions, I would recommend this book to clinicians as well as statisticians who are working in this challenging and developing area of research." -Susan Ellenberg, Journal of the American Statistical Association"Design and Analysis of Clinical Trials for Predictive Medicine addresses a necessity for precision medicine: identifying and testing molecular biomarkers for their ability to predict the effect of treatments on specific patient populations."~Journal of Clinical Research Best Practices, December 2015"… a very good collection of relevant topics and methods, which have been published and applied in the field of personalized medicine from a clinical development perspective. The editors of this book are experts in the field and have published extensively on these topics. … a useful reference for biostatisticians and researchers involved in the design and analyses of biomarker integrated clinical trials."~Arunava Chakravartty, Journal of Biopharmaceutical Statistics"…a useful resource for clinical biostatisticians, researchers focusing on predictive medicine, clinical investigators, translational scientists, and graduate biostatistics students."~Zentralblatt MATH"The book, edited by three leading experts in methodology of clinical trials, includes 18 chapters divided in six sections written by 36 statisticians and other methodologists with longstanding experience in academia, industry, funding agencies, and regulatory authorities. The book covers all aspects of clinical trial design from the early stages of assay validation to later phase I, II, and III trials. It also provides guidance on statistical methods for the analysis of data generated at the different stages. This comprehensive coverage of the“natural history” of drug and biomarker development can help researchers better understand the challenges encountered by their colleagues in previous or subsequent phases of this pipeline. Despite being an edited book, the concepts are well-integrated across the chapters and, most of the time, the transition from one topic to the other is done in a natural way for the reader. . . . I found the book a very informative introduction to a new kind of clinical trials that will become more common in the future years as the community intensifies the pursuit of “individualized treatments.”~The International Biometric Society"In reading the book, one gains somewhat of a “double education”, in that through reading about the statistical concepts used in a setting, one’s understanding of the disease biology is enriched, and vice versa."~Emma YuWang, International Society for Clinical Biostatistics

Shigeyuki Matsui is a professor in the Department of Biostatistics at Nagoya University Graduate School of Medicine in Japan. He is also a visiting professor at the Institute of Statistical Mathematics. Dr. Matsui has served as council and nominating committee member of the International Biometric Society. He is currently council of the Biometric Society of Japan (BSJ) and editor-in-chief of the Japanese Journal of Biometrics. He is the recipient of the 2014 Award from the BSJ. Dr. Matsui is also a frequent reviewer commissioned by government and advisor to pharmaceutical companies in Japan. He holds degrees in engineering from the Tokyo University of Science in Japan.Marc E. Buyse is the founder of the International Drug Development Institute in Louvain-la-Neuve, Belgium and of CluePoints Inc. in Cambridge, Massachusetts. He is also an associate professor of biostatistics at Hasselt University in Belgium. He was president of the International Society for Clinical Biostatistics, president of the Quetelet Society, and fellow of the Society for Clinical Trials. He worked at the European Organization for Research and Treatment of Cancer in Brussels and at the Dana Farber Cancer Institute in Boston. He holds degrees in engineering and statistics from Brussels University, management from the Cranfield School of Management in the UK, and a doctorate in biostatistics from Harvard University.Richard M. Simon is chief of the Biometric Research Branch at the National Cancer Institute in Bethesda, Maryland. He leads a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. Dr. Simon is the architect of BRB-ArrayTools software used for the analysis of microarray and digital expression, copy number, and methylation data. He is the recipient of the 2013 Karl E. Peace Award for Outstanding Statistical Contributions for the Betterment of Society and is the author or coauthor of more than 450 publications.

• INTRODUCTORY OVERVIEW. Clinical Trials for Predictive Medicine: New Paradigms and Challenges. An Industry Statistician’s Perspective on Personalized Health Care Drug Development. Analytical Validation of In Vitro Diagnostic Tests. EARLY CLINICAL TRIALS USING BIOMARKERS. Phase I Dose-Finding Designs and Their Applicability to Targeted Therapies. An Overview of Phase II Clinical Trial Designs with Biomarkers. Bayesian Adaptive Methods for Clinical Trials of Targeted Agents. Outcome-Adaptive Randomization in Early Clinical Trials. Challenges of Using Predictive Biomarkers in Clinical Trials. PHASE III RANDOMIZED CLINICAL TRIALS USING BIOMARKERS. Comparison of Randomized Clinical Trial Designs for Targeted Agents. Phase III All-Comers Clinical Trials with a Predictive Biomarker. Evaluation of Clinical Utility and Validation of Gene Signatures in Clinical Trials. ANALYSIS OF HIGH-DIMENSIONAL DATA AND GENOMIC SIGNATURE DEVELOPMENTS. Statistical Issues in Clinical Development and Validation of Genomic Signatures. Univariate Analysis for Gene Screening: Beyond Multiple Testing. Statistical and Machine-Learning Methods for Class Prediction in High Dimension. Survival Risk Prediction Using High-Dimensional Molecular Data. RANDOMIZED TRIALS WITH BIOMARKER DEVELOPMENT AND VALIDATION. Adaptive Clinical Trial Designs with Biomarker Development and Validation. Development and Validation of Continuous Genomic Signatures in Randomized Clinical Trials. EVALUATION OF SURROGATE BIOMARKERS. Biomarker-Based Surrogate Endpoints.

"To say this is an extremely timely book would be a gross understatement. The editors have assembled an impressive series of articles that address many of the major methodological issues confronting researchers who are attempting to not only identify valuable medical treatments but to determine which subsets of patients will benefit from these treatments. These issues are particularly important in cancer research, where treatments are often burdensome, toxic, and expensive; one does not want to treat large numbers of patients when only a few will benefit …[this] would be a very valuable resource for anyone in, or moving into, the area of clinical trials for developing targeted therapies. Because the chapters steer away from highly technical discussions, I would recommend this book to clinicians as well as statisticians who are working in this challenging and developing area of research." -Susan Ellenberg, Journal of the American Statistical Association"Design and Analysis of Clinical Trials for Predictive Medicine addresses a necessity for precision medicine: identifying and testing molecular biomarkers for their ability to predict the effect of treatments on specific patient populations."~Journal of Clinical Research Best Practices, December 2015"… a very good collection of relevant topics and methods, which have been published and applied in the field of personalized medicine from a clinical development perspective. The editors of this book are experts in the field and have published extensively on these topics. … a useful reference for biostatisticians and researchers involved in the design and analyses of biomarker integrated clinical trials."~Arunava Chakravartty, Journal of Biopharmaceutical Statistics"…a useful resource for clinical biostatisticians, researchers focusing on predictive medicine, clinical investigators, translational scientists, and graduate biostatistics students."~Zentralblatt MATH"The book, edited by three leading experts in methodology of clinical trials, includes 18 chapters divided in six sections written by 36 statisticians and other methodologists with longstanding experience in academia, industry, funding agencies, and regulatory authorities. The book covers all aspects of clinical trial design from the early stages of assay validation to later phase I, II, and III trials. It also provides guidance on statistical methods for the analysis of data generated at the different stages. This comprehensive coverage of the“natural history” of drug and biomarker development can help researchers better understand the challenges encountered by their colleagues in previous or subsequent phases of this pipeline. Despite being an edited book, the concepts are well-integrated across the chapters and, most of the time, the transition from one topic to the other is done in a natural way for the reader. . . . I found the book a very informative introduction to a new kind of clinical trials that will become more common in the future years as the community intensifies the pursuit of “individualized treatments.”~The International Biometric Society"In reading the book, one gains somewhat of a “double education”, in that through reading about the statistical concepts used in a setting, one’s understanding of the disease biology is enriched, and vice versa."~Emma YuWang, International Society for Clinical Biostatistics

Shigeyuki Matsui is a professor in the Department of Biostatistics at Nagoya University Graduate School of Medicine in Japan. He is also a visiting professor at the Institute of Statistical Mathematics. Dr. Matsui has served as council and nominating committee member of the International Biometric Society. He is currently council of the Biometric Society of Japan (BSJ) and editor-in-chief of the Japanese Journal of Biometrics. He is the recipient of the 2014 Award from the BSJ. Dr. Matsui is also a frequent reviewer commissioned by government and advisor to pharmaceutical companies in Japan. He holds degrees in engineering from the Tokyo University of Science in Japan.Marc E. Buyse is the founder of the International Drug Development Institute in Louvain-la-Neuve, Belgium and of CluePoints Inc. in Cambridge, Massachusetts. He is also an associate professor of biostatistics at Hasselt University in Belgium. He was president of the International Society for Clinical Biostatistics, president of the Quetelet Society, and fellow of the Society for Clinical Trials. He worked at the European Organization for Research and Treatment of Cancer in Brussels and at the Dana Farber Cancer Institute in Boston. He holds degrees in engineering and statistics from Brussels University, management from the Cranfield School of Management in the UK, and a doctorate in biostatistics from Harvard University.Richard M. Simon is chief of the Biometric Research Branch at the National Cancer Institute in Bethesda, Maryland. He leads a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. Dr. Simon is the architect of BRB-ArrayTools software used for the analysis of microarray and digital expression, copy number, and methylation data. He is the recipient of the 2013 Karl E. Peace Award for Outstanding Statistical Contributions for the Betterment of Society and is the author or coauthor of more than 450 publications.

• INTRODUCTORY OVERVIEW. Clinical Trials for Predictive Medicine: New Paradigms and Challenges. An Industry Statistician’s Perspective on Personalized Health Care Drug Development. Analytical Validation of In Vitro Diagnostic Tests. EARLY CLINICAL TRIALS USING BIOMARKERS. Phase I Dose-Finding Designs and Their Applicability to Targeted Therapies. An Overview of Phase II Clinical Trial Designs with Biomarkers. Bayesian Adaptive Methods for Clinical Trials of Targeted Agents. Outcome-Adaptive Randomization in Early Clinical Trials. Challenges of Using Predictive Biomarkers in Clinical Trials. PHASE III RANDOMIZED CLINICAL TRIALS USING BIOMARKERS. Comparison of Randomized Clinical Trial Designs for Targeted Agents. Phase III All-Comers Clinical Trials with a Predictive Biomarker. Evaluation of Clinical Utility and Validation of Gene Signatures in Clinical Trials. ANALYSIS OF HIGH-DIMENSIONAL DATA AND GENOMIC SIGNATURE DEVELOPMENTS. Statistical Issues in Clinical Development and Validation of Genomic Signatures. Univariate Analysis for Gene Screening: Beyond Multiple Testing. Statistical and Machine-Learning Methods for Class Prediction in High Dimension. Survival Risk Prediction Using High-Dimensional Molecular Data. RANDOMIZED TRIALS WITH BIOMARKER DEVELOPMENT AND VALIDATION. Adaptive Clinical Trial Designs with Biomarker Development and Validation. Development and Validation of Continuous Genomic Signatures in Randomized Clinical Trials. EVALUATION OF SURROGATE BIOMARKERS. Biomarker-Based Surrogate Endpoints.

"To say this is an extremely timely book would be a gross understatement. The editors have assembled an impressive series of articles that address many of the major methodological issues confronting researchers who are attempting to not only identify valuable medical treatments but to determine which subsets of patients will benefit from these treatments. These issues are particularly important in cancer research, where treatments are often burdensome, toxic, and expensive; one does not want to treat large numbers of patients when only a few will benefit …[this] would be a very valuable resource for anyone in, or moving into, the area of clinical trials for developing targeted therapies. Because the chapters steer away from highly technical discussions, I would recommend this book to clinicians as well as statisticians who are working in this challenging and developing area of research." -Susan Ellenberg, Journal of the American Statistical Association"Design and Analysis of Clinical Trials for Predictive Medicine addresses a necessity for precision medicine: identifying and testing molecular biomarkers for their ability to predict the effect of treatments on specific patient populations."~Journal of Clinical Research Best Practices, December 2015"… a very good collection of relevant topics and methods, which have been published and applied in the field of personalized medicine from a clinical development perspective. The editors of this book are experts in the field and have published extensively on these topics. … a useful reference for biostatisticians and researchers involved in the design and analyses of biomarker integrated clinical trials."~Arunava Chakravartty, Journal of Biopharmaceutical Statistics"…a useful resource for clinical biostatisticians, researchers focusing on predictive medicine, clinical investigators, translational scientists, and graduate biostatistics students."~Zentralblatt MATH"The book, edited by three leading experts in methodology of clinical trials, includes 18 chapters divided in six sections written by 36 statisticians and other methodologists with longstanding experience in academia, industry, funding agencies, and regulatory authorities. The book covers all aspects of clinical trial design from the early stages of assay validation to later phase I, II, and III trials. It also provides guidance on statistical methods for the analysis of data generated at the different stages. This comprehensive coverage of the“natural history” of drug and biomarker development can help researchers better understand the challenges encountered by their colleagues in previous or subsequent phases of this pipeline. Despite being an edited book, the concepts are well-integrated across the chapters and, most of the time, the transition from one topic to the other is done in a natural way for the reader. . . . I found the book a very informative introduction to a new kind of clinical trials that will become more common in the future years as the community intensifies the pursuit of “individualized treatments.”~The International Biometric Society"In reading the book, one gains somewhat of a “double education”, in that through reading about the statistical concepts used in a setting, one’s understanding of the disease biology is enriched, and vice versa."~Emma YuWang, International Society for Clinical Biostatistics